Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Investigating the biology of microRNA links to ALDH1A1 reveals candidates for preclinical testing in acute myeloid leukemia.
Int J Oncol
December 2024
Biomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 11635 Athens, Greece.
Article Synopsis
- ALDH1A1 is an enzyme that oxidizes retinaldehyde and its high RNA levels are linked to poor outcomes in acute myeloid leukemia (AML).
- Agents exist to inhibit ALDH activity, but there's a need for adjustable genetic methods to target multiple cancer pathways simultaneously.
- MicroRNAs (miRNAs) have emerged as important regulators of gene expression in AML and some have the potential to directly affect ALDH1A1, making them promising candidates for genetic interventions in AML treatment.
Reactive oxygen species and aldehyde dehydrogenase 1A as prognosis and theragnostic biomarker in acute myeloid leukaemia patients.
J Cell Mol Med
October 2024
APHM, Hôpital de la Conception, Service d'Hématologie et Thérapie Cellulaire, Marseille, France.
Acute myeloid leukaemia (AML) remains a major unmet medical, despite recent progress in targeted molecular therapies. One aspect of leukaemic cell resistance to chemotherapy is the development of clones with increased capacity to respond to cellular stress and the production of reactive oxygen species (ROS), thanks in particular to a high aldehyde dehydrogenases (ALDH) 1A1/2 activity. At diagnosis, ROS level and ALDH1A1/2 activity in AML patients BM are correlated with the different ELN 2022 prognostic groups and overall survival (OS).
View Article and Find Full Text PDFSelective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.
Leukemia
December 2024
Department of Toxicology, University Medical Center, 55131, Mainz, Germany.
Internal tandem duplications in the FMS-like tyrosine kinase-3 (FLT3-ITD) are common mutations in acute myeloid leukemia (AML). Proteolysis-targeting chimeras (PROTACs) that induce proteasomal degradation of mutated FLT3 emerge as innovative pharmacological approach. Molecular mechanisms that control targeted proteolysis beyond the ubiquitin-proteasome-system are undefined and PROTACs are the only known type of FLT3 degraders.
View Article and Find Full Text PDFBilateral optic nerve infiltration and leukemic retinopathy as initial signs of leukemia relapse with central nervous system involvement in an adult: a case report.
BMC Ophthalmol
May 2024
Department of Ophthalmology, Peking University Shougang Hospital, 9# Jinyuanzhuang Road, Shijingshan district, Beijing, 100144, China.
Background: We describe a case in which bilateral optic nerve infiltration and leukemic retinopathy were the initial signs of disease relapse in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) with central nervous system (CNS) involvement.
Case Presentation: A 65-year-old Asian female with Ph-ALL in complete remission presented at our institution with symptoms of visual disturbance, central scotoma and pain with eye movement in both eyes for a 1-month duration. Ophthalmic examination revealed remarkable optic disc swelling with multiple flame-shaped peripapillary hemorrhages, retinal venous dilation and retinal hemorrhages in both eyes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!